Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Upadacitinib efficacy proves to be greater than placebo, and non-inferior to adalimumab, in treating patients with psoriatic arthritis (PsA).
Already approved for the treatment of rheumatoid arthritis, McInnes, et al. studied oral upadacitinib at a dose of 15 mg or 30 mg, alongside placebo or adalimumab, in this 24-week, Phase III trial, in over 1700 patients with PsA. At the primary endpoint (Week 12), ACR20 response was greater with upadacitinib than placebo, and non-inferior to adalimumab; with the 30 mg dose being superior to adalimumab.
Safety conclusions are limited due to the duration of the study; longer and larger trials will help to determine the overall effects and risks of upadacitinib in patients with PsA.